Skip to content
To the full analysis

Intco Medical Technology Stock: Balance Sheet and Debt

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

Intco Medical Technology has a debt to equity ratio of 0.95 and an interest coverage of 4.3x. Since the end of 2025 debt has exceeded cash, at the end of 2024 it was the other way round.

Daily figure as of 20 Nov 2026

Debt / Equity
0.95
Interest coverage
4.3x
Current ratio
0.85
Cash & equivalents
$1.98B
Total assets
$6.01B
Equity ratio
46.3%
Goodwill and intangible assets
$109.37M
not split out
Net debt
$656.91M

Balance Sheet Over Time

At the end of 2024 cash still exceeded debt by $887.77M. Interest coverage fell from over 100x in 2020 to 4.3x.

Total Assets and Equity Ratio

How large the balance sheet of Intco Medical Technology Co., Ltd. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2013$105.67M$2.4Mnot split out21.0%$24.92M
2014$98.48M$2.85Mnot split out25.6%$27.47M
2015$113.12M$3.2Mnot split out55.1%$13.82M
2016$174.56M$4.84Mnot split out46.0%$38.13M
2017$248.74M$4.81Mnot split out65.6%−$9.39M
2018$363.69M$13.74Mnot split out52.5%−$6.27M
2019$448.8M$29.3Mnot split out50.2%$18.9M
2020$1.94B$52.42Mnot split out73.0%−$920.72M
2021$3.09B$94.49Mnot split out78.2%−$1.2B
2022$3.22B$87.52Mnot split out74.7%−$766.46M
2023$4.06B$85.03Mnot split out60.2%−$802.06M
2024$5.19B$115.05Mnot split out51.1%−$887.77M
2025$6.01B$109.37Mnot split out46.3%$656.91M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and Debt

What the Company Owns and Owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2013$7.92M$21.92M$32.84M1.48
2014$15.56M$25.26M$43.03M1.7
2015$9.25M$62.28M$23.07M0.37
2016$15.88M$80.32M$54.01M0.67
2017$47.03M$163.13M$37.64M0.23
2018$128.69M$190.96M$122.42M0.64
2019$130.83M$221.6M$149.73M0.66
2020$958.56M$1.4B$37.84M0.03
2021$1.24B$2.38B$38.27M0.02
2022$998.57M$2.37B$232.11M0.1
2023$1.87B$2.4B$1.07B0.44
2024$2.81B$2.61B$1.92B0.73
2025$1.98B$2.74B$2.64B0.95

Debt to equity divides debt by total equity, including non-controlling interests, as S&P calculates it. The equity column shows the part that belongs to shareholders.

Debt of Industry Peers

Intco Medical Technology's debt to equity is higher than that of 80 of 81 other stocks in the Healthcare sector.

StockDebt to equityEquity ratio
Asahi Intecc0.0579.9%
Teleflex0.8745.0%
Gan & Lee Pharmaceuticals.0.0192.1%
Merit Medical Systems0.5759.0%
Intco Medical Technology0.9546.3%
ICU Medical0.6652.4%
Stevanato Group0.3258.4%
Envista Holdings0.5154.7%
SCHOTT Pharma0.0954.5%

Figures from the latest fiscal year. The eight peers closest in market value, largest first.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.